Clinical Trial


Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)


Brief description

The purpose of this study is to see if fluticasone 500mcg/salmeterol 50mcg can improve the survival of subjects with COPD and also assess the long term safety profile of this drug.

Detailed Description

A multicenter, randomized, double-blind, parallel group, placebo controlled study to investigate the effects of salmeterol/fluticasone 50/500mcg bd, salmeterol 50mcg bd, and fluticasone 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease over 3 years of treatment.

Keywords

  •   Pulmonary Disease, Chronic Obstructive

Sponsored By

GlaxoSmithKline

Unique Study ID

NCT00268216

Investigators and Research Sites Near You - Found( 3 )

No Investigator Listed

Sanofi
B15 2GW, Birmingham, United Kingdom
Distance from Current Trial is 0 miles

Jereme D Wilroy, PhD

University of Alabama at Birmingham
35209, Birmingham, Alabama, United States
Distance from Current Trial is 0 miles

Ansar Mahmood

University of Aberdeen
B15 2TH, Birmingham, United Kingdom
Distance from Current Trial is 0 miles
View All